X-ray photon absorption by iodine

X-ray photon absorption by iodine is not a therapeutic target in the conventional sense used in drug development and biomedical research. Therapeutic targets are typically biological molecules (e.g., receptors, enzymes, transporters) that can be modulated by drugs to produce a therapeutic effect. Instead, X-ray photon absorption by iodine is a fundamental physical/chemical interaction where iodine atoms or iodine-containing contrast agents absorb X-ray photons, primarily via the photoelectric effect, and generate secondary electrons. This phenomenon is extensively exploited in medical imaging, where iodinated contrast media (ICM) are used to enhance contrast in radiographic techniques due to their high X-ray absorption properties. However, the absorption itself is a physical process, not a 'target' that drugs aim to modulate therapeutically. While iodine is integral to imaging agents like Iodixanol, these are diagnostic tools, not therapeutic drugs. The *effect* of this absorption, such as the generation of secondary electrons, can lead to biological impacts like DNA damage, but this is a consequence of the physical interaction rather than a therapeutic targeting mechanism. Relevant pharmaceutical targets related to iodine contrast agents would include the contrast media formulations themselves (as imaging agents) or biological targets that might be inadvertently affected by contrast agent exposure.

Other names

Iodine K-edge absorptionPhotoelectric effect by iodine